Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Pharm Biotechnol ; 9(4): 239-41, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18691082

ABSTRACT

Presently, the two main commercial sources of hyaluronic acid (HA) are rooster combs and streptococci. Harvesting from rooster combs is complex and costly. Streptococci are difficult to genetically manipulate and require complex media for growth. Both sources have potential problems with unwanted by-products, such as allergens and toxins. These problems can be solved by producing the HA with safe bacilli that are expressing a recombinant HA synthase (HAS).


Subject(s)
Bacillus subtilis/metabolism , Biotechnology/methods , Glucuronosyltransferase , Hyaluronic Acid/biosynthesis , Recombinant Proteins , Bacillus subtilis/genetics , Bacillus subtilis/growth & development , Fermentation , Glucuronosyltransferase/genetics , Glucuronosyltransferase/metabolism , Hyaluronan Synthases , Hyaluronic Acid/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Uridine Diphosphate Glucuronic Acid/genetics , Uridine Diphosphate Glucuronic Acid/metabolism , Uridine Diphosphate N-Acetylglucosamine/genetics , Uridine Diphosphate N-Acetylglucosamine/metabolism
2.
Biochim Biophys Acta ; 1770(2): 286-90, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17095162

ABSTRACT

Hyaluronan (HA), a linear polysaccharide composed of beta1,3-GlcNAc-beta1,4-GlcUA repeats, is found in the extracellular matrix of vertebrate tissues as well as the capsule of several pathogenic bacteria. All known HA synthases (HASs) are dual-action glycosyltransferases that catalyze the addition of two different sugars from UDP-linked precursors to the growing HA chain. The bacterial hyaluronan synthase, PmHAS from Gram-negative Pasteurella multocida, is a 972-residue membrane-associated protein. Previously, the Gram-positive Streptococcus pyogenes enzyme, SpHAS (419 residues), and the vertebrate enzyme, XlHAS1 (588 residues), were found to function as monomers of protein, but the PmHAS is not similar at the protein sequence level and has quite different enzymological properties. We have utilized radiation inactivation to measure the target size of recombinant full-length and truncated PmHAS. The target size of HAS activity was confirmed using internal enzyme standards of known molecular weight. We found that the Pasteurella HA synthase protein functions catalytically as a monomer. Functional truncated soluble PmHAS also behaves as a polypeptide monomer as assessed by gel filtration chromatography and light scattering.


Subject(s)
Glucuronosyltransferase/chemistry , Glucuronosyltransferase/metabolism , Pasteurella multocida/enzymology , Bacterial Proteins/chemistry , Bacterial Proteins/isolation & purification , Chromatography, Gel , Cloning, Molecular , Escherichia coli/enzymology , Escherichia coli/genetics , Glucosephosphate Dehydrogenase/metabolism , Glucuronosyltransferase/isolation & purification , Glucuronosyltransferase/radiation effects , Hyaluronan Synthases , Molecular Weight , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
3.
J Biol Chem ; 280(10): 8813-8, 2005 Mar 11.
Article in English | MEDLINE | ID: mdl-15623518

ABSTRACT

Hyaluronan (HA), a functionally essential glycosaminoglycan in vertebrate tissues and a putative virulence factor in certain pathogenic bacteria, is an extended linear polymer composed of alternating units of glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). Uncertainty regarding the mechanism of HA biosynthesis has included the directionality of chain elongation, i.e. whether addition of monosaccharide units occurs at the reducing or non-reducing terminus of nascent chains. We have investigated this problem using yeast-derived recombinant HA synthases from Xenopus laevis (xlHAS1) and from Streptococcus pyogenes (spHAS). The enzymes were incubated with UDP-[3H]GlcUA and UDP-[14C]GlcNAc, under experimental conditions designed to yield HA chains with differentially labeled reducing-terminal and non-reducing terminal domains. Digestion of the products with a mixture of beta-glucuronidase and beta-N-acetylglucosaminidase exoenzymes resulted in truncation of the HA chain strictly from the non-reducing end and release of labeled monosaccharides. The change in 3H/14C ratio of the monosaccharide fraction, during the course of exoglycosidase digestion, was interpreted to indicate whether sugar units had been added at the reducing or non-reducing end. The results demonstrate that the vertebrate xlHAS1 and the bacterial spHAS extend HA in opposite directions. Chain elongation catalyzed by xlHAS1 occurs at the non-reducing end of the HA chain, whereas elongation catalyzed by spHAS occurs at the reducing end. The spHAS is the first glycosyltransferase that has been unanimously demonstrated to function at the reducing end of a growing glycosaminoglycan chain.


Subject(s)
Hyaluronic Acid/biosynthesis , Transferases/metabolism , Animals , Bacterial Proteins/metabolism , Carbohydrate Sequence , Glucuronosyltransferase , Hyaluronan Synthases , Kinetics , Molecular Sequence Data , Streptococcus pyogenes/enzymology , Xenopus Proteins/metabolism , Xenopus laevis
4.
J Biol Chem ; 278(22): 19808-14, 2003 May 30.
Article in English | MEDLINE | ID: mdl-12654925

ABSTRACT

Hyaluronan (HA) is a nonsulfated glycosaminoglycan that has long been known to play structural roles in vertebrates. Recently, it has become increasingly obvious that this linear polysaccharide has many more uses than simply scaffolding or space filler. HA has been found to be involved in development, cell signaling, cell motility, and metastasis. These roles are often dictated by the length of the HA polymer, which can vary from a few to about 10,000 sugar residues in length. Three distinct isoforms of HA synthase exist in mammals. It has been shown previously by others that each isoform produces HA that differs in size distribution, but the regulatory mechanism is not yet known. Mutations have been described that alter the size distribution of the HA produced by the streptococcal HA synthases. We show that by mutating one particular amino acid residue of a vertebrate HA synthase, depending on the introduced side chain, the size of HA produced can be either reduced or increased. We postulate that several cysteine residues and a serine residue may be involved in binding directly or indirectly to the nascent HA chain. These data support the theory that the relative strength of the interaction between the catalyst and the polymer may be a major factor in HA size control.


Subject(s)
Glucuronosyltransferase/metabolism , Glycosyltransferases , Membrane Proteins , Polysaccharides/chemistry , Transferases , Xenopus Proteins , Amino Acid Sequence , Chromatography, Gel , Electrophoresis, Agar Gel , Glucuronosyltransferase/chemistry , Glucuronosyltransferase/isolation & purification , Hyaluronan Synthases , Kinetics , Molecular Sequence Data , Sequence Homology, Amino Acid
5.
J Biol Chem ; 277(24): 21610-6, 2002 Jun 14.
Article in English | MEDLINE | ID: mdl-11943783

ABSTRACT

The hyaluronan (HA) synthases catalyze the addition of two different monosaccharides from UDP-sugar substrates to the linear heteropolysaccharide chain. To accomplish this task, the HA synthases must be able to bind and to transfer from both UDP-sugar substrates. Until now, it has been impossible to distinguish between these two abilities. We have created a mutant of xlHAS1, a HA synthase from Xenopus laevis, that allows for the examination of the enzyme's ability to bind substrate only. The ability of different compounds to protect the xlHAS1(C337S) mutant enzyme from loss of activity due to treatment with N-ethylmaleimide, a cysteine-modifying reagent, yields information on the relative affinity of a variety of nucleotides and nucleotide-sugars. We have observed that the substrate binding selectivity is more relaxed than the specificity of catalytic transfer. The only attribute that appears to be absolutely required for binding is a nucleotide containing two phosphates complexed with magnesium ion. The role of certain cysteine residues in catalysis was also evaluated. Cys307 of xlHAS1 may play a role in catalysis or in maintaining structure. Mutation of Cys337 raises the UDP-GlcUA Michaelis constant (K(m)), suggesting that this residue participates in UDP-GlcUA substrate binding or in catalytic complex formation.


Subject(s)
Cysteine/chemistry , Glucuronosyltransferase/chemistry , Glycosyltransferases , Membrane Proteins , Transferases , Uridine Diphosphate Sugars/chemistry , Xenopus Proteins , Animals , Binding Sites , Catalysis , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Ethylmaleimide/pharmacology , Hyaluronan Synthases , Kinetics , Mutation , Polysaccharides/chemistry , Protein Binding , Recombinant Proteins/metabolism , Substrate Specificity , Sulfhydryl Reagents/pharmacology , Xenopus laevis
SELECTION OF CITATIONS
SEARCH DETAIL
...